
“The quality and coverage of B2B contact database are very impressive...”
Mark J.
`
ENYO Pharma is developing innovative therapeutics based on fibrolytic and anti-inflammatory properties for diseases with impaired kidney function. The company is conducting Phase 2 trials with its lead compound Vonafexor in Chronic Kidney Diseases (CKD) and rare kidney disease such as Alport syndrome, and liver diseases (such as Non-Alcoholic SteatoHepatitis, NASH). Liver-related infectious diseases such as chronic Hepatitis B and Hepatitis D are also addressed with Vonafexor
Enyo pharma operates in the Biotechnology research industry.
Enyo pharma's revenue is 11m - 100m
Enyo pharma has 11 - 50 employees.
Get Started with the Free Forever plan! No credit card needed. Enjoy up to 10,000 free email credits per month at no cost.
Start Prospecting from Clodura.AI's database of 600M+ verified B2B contacts and 120M+ direct dials along with 18M+ companies' org charts.
Unlock the prospect's contact details, including verified email, direct dials, add them to cadence, and close more deals.